Non-Coding Rnas in Leukemia Drug Resistance: New Perspectives on Molecular Mechanisms and Signaling Pathways Publisher Pubmed



Rahmati A^{1, 2} ; Mafi A³ ; Vakili O⁴ ; Soleymani F⁵ ; Alishahi Z² ; Yahyazadeh S⁶ ; Gholinezhad Y⁷ ; Rezaee M^{8, 9} ; Johnston TP¹⁰ ; Sahebkar A^{11, 12, 13}
Source: Annals of Hematology Published:2024

Abstract

Like almost all cancer types, timely diagnosis is needed for leukemias to be effectively cured. Drug efflux, attenuated drug uptake, altered drug metabolism, and epigenetic alterations are just several of the key mechanisms by which drug resistance develops. All of these mechanisms are orchestrated by up- and downregulators, in which non-coding RNAs (ncRNAs) do not encode specific proteins in most cases; albeit, some of them have been found to exhibit the potential for protein-coding. Notwithstanding, ncRNAs are chiefly known for their contribution to the regulation of physiological processes, as well as the pathological ones, such as cell proliferation, apoptosis, and immune responses. Specifically, in the case of leukemia chemo-resistance, ncRNAs have been recognized to be responsible for modulating the initiation and progression of drug resistance. Herein, we comprehensively reviewed the role of ncRNAs, specifically its effect on molecular mechanisms and signaling pathways, in the development of leukemia drug resistance. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023.